ME03359B - 2 suptiтuisana cefemska jedinjenja - Google Patents

2 suptiтuisana cefemska jedinjenja

Info

Publication number: ME03359B
Authority: ME; Montenegro
Prior art keywords: subtituated; cefem compounds; cefem; compounds; subtituated cefem
Prior art date: 2012-10-29

Application number

MEP-2019-61A

Other languages

German (de)

English (en)

French (fr)

Inventor

Xiangmin Liao

Neil David Pearson

Israil Pendrak

Reema Thalgi

Kenji Yamawaki

Katsuki Yokoo

Jun Sato

Hiroki Kusano

Toshiaki Aoki

Original Assignee

Glaxo Group Ltd

Shionogi & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-29

Filing date

2013-10-29

Publication date

2019-10-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49955387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03359(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-29 Application filed by Glaxo Group Ltd, Shionogi & Co filed Critical Glaxo Group Ltd

2019-10-20 Publication of ME03359B publication Critical patent/ME03359B/me

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/48—Methylene radicals, substituted by hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/48—Methylene radicals, substituted by hetero rings
- C07D501/50—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
- C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
- C07D505/16—Nitrogen atoms
- C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
- C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Cephalosporin Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epidemiology (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MEP-2019-61A 2012-10-29 2013-10-29 2 suptiтuisana cefemska jedinjenja ME03359B (me)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261719523P	2012-10-29	2012-10-29
PCT/IB2013/002423 WO2014068388A1 (en)	2012-10-29	2013-10-29	2 substituted cephem compounds
EP13820853.3A EP2917223B1 (en)	2012-10-29	2013-10-29	2 substituted cephem compounds

Publications (1)

Publication Number	Publication Date
ME03359B true ME03359B (me)	2019-10-20

Family

ID=49955387

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2019-61A ME03359B (me)	2012-10-29	2013-10-29	2 suptiтuisana cefemska jedinjenja

Country Status (38)

Country	Link
US (2)	US20150299223A1 (me)
EP (1)	EP2917223B1 (me)
JP (1)	JP6316830B2 (me)
KR (1)	KR20150081428A (me)
CN (2)	CN107652310A (me)
AR (1)	AR093261A1 (me)
AU (2)	AU2013340469B2 (me)
BR (2)	BR122016025225A2 (me)
CA (1)	CA2889746A1 (me)
CL (1)	CL2015001084A1 (me)
CR (1)	CR20150224A (me)
CY (1)	CY1121721T1 (me)
DK (1)	DK2917223T3 (me)
EA (1)	EA031881B1 (me)
ES (1)	ES2717923T3 (me)
HR (1)	HRP20190603T1 (me)
HU (1)	HUE042664T2 (me)
IL (1)	IL238149A (me)
LT (1)	LT2917223T (me)
MA (1)	MA38039A1 (me)
ME (1)	ME03359B (me)
MX (1)	MX365534B (me)
MY (1)	MY176987A (me)
NZ (1)	NZ628527A (me)
PE (1)	PE20151204A1 (me)
PH (2)	PH12015500914A1 (me)
PL (1)	PL2917223T3 (me)
PT (1)	PT2917223T (me)
RS (1)	RS58611B1 (me)
SG (2)	SG10201703589TA (me)
SI (1)	SI2917223T1 (me)
SM (1)	SMT201900209T1 (me)
TR (1)	TR201904001T4 (me)
TW (1)	TWI625333B (me)
UA (1)	UA117666C2 (me)
UY (1)	UY35103A (me)
WO (1)	WO2014068388A1 (me)
ZA (1)	ZA201502174B (me)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112015008905A2 (pt) *	2012-10-29	2017-07-04	Shionogi & Co	processos para a produção de intermediários de compostos de 2-alquil cefem
ES2949648T3 (es)	2012-12-20	2023-10-02	Purdue Research Foundation	Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
CN105073759A (zh) *	2012-12-26	2015-11-18	盐野义制药株式会社	头孢烯化合物
JP6377570B2 (ja) *	2014-04-28	2018-08-22	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	２−置換セフェム化合物を含有する医薬組成物
PH12017500435B1 (en) *	2014-09-04	2023-12-06	Shionogi & Co	A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
CN107074823B (zh)	2014-09-05	2021-05-04	基因泰克公司	治疗性化合物及其用途
JP6767969B2 (ja) *	2014-09-05	2020-10-14	ジェネンテック，インコーポレイテッド	がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体
CN104529735A (zh) *	2014-12-08	2015-04-22	苏州施亚生物科技有限公司	一种1-(5-溴-4-氯-2-氟苯基)-乙酮的合成方法
JP6659703B2 (ja)	2015-01-09	2020-03-04	ジェネンテック，インコーポレイテッド	ピリダジノン誘導体および癌の処置におけるそれらの使用
AU2016275764B8 (en)	2015-06-11	2021-03-04	Basilea Pharmaceutica International AG	Efflux-pump inhibitors and therapeutic uses thereof
HK1247607A1 (zh) *	2015-06-11	2018-09-28	高等教育联邦系统-匹兹堡大学	P62-zz化学抑制剂
US9765026B2 (en) *	2015-08-28	2017-09-19	Scinopharm Taiwan, Ltd.	Forms of apremilast and the process of making the same
US9751894B2 (en) *	2015-12-10	2017-09-05	Naeja-Rgm Pharmaceuticals Inc.	Cephem compounds, their production and use
JP7282521B2 (ja)	2016-04-08	2023-05-29	パーデュー・リサーチ・ファウンデイション	Ｃａｒｔ細胞療法のための方法および組成物
CN110612119B (zh)	2017-02-07	2024-10-29	西雅图儿童医院（Dba西雅图儿童研究所）	磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
US11850262B2 (en)	2017-02-28	2023-12-26	Purdue Research Foundation	Compositions and methods for CAR T cell therapy
CN106966914B (zh) *	2017-05-04	2019-02-22	无锡捷化医药科技有限公司	一种5-溴-4-氯-2-氨基苯乙酮的制备方法
BR112020014913A2 (pt)	2018-01-22	2020-12-08	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Métodos para uso de células t car
SG11202007426XA (en)	2018-02-06	2020-09-29	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CA3091674A1 (en)	2018-02-23	2019-08-29	Endocyte, Inc.	Sequencing method for car t cell therapy
CN108892639B (zh) *	2018-08-13	2021-05-14	云南民族大学	一种高效环保制备喹诺酮类化合物的方法
CN113024582A (zh) *	2020-03-04	2021-06-25	刀鹏	一种盐酸头孢吡肟的合成方法
EP4279491A4 (en) *	2021-01-12	2024-07-24	Shanghai Senhui Medicine Co., Ltd.	Cephalosporin antibacterial compound and preparation method therefor
CN113698365A (zh) *	2021-08-30	2021-11-26	成都大学	一种头孢地尔侧链的制备方法
CN116514679A (zh) *	2023-04-03	2023-08-01	南京工业大学	一种以廉价高效的硝酸季铵盐作为氧化剂的钯催化sp2和sp3碳氢键烯基化方法
GB202306826D0 (en)	2023-05-09	2023-06-21	Adjutec Pharma As	Therapy
CN116804001A (zh) *	2023-06-26	2023-09-26	江苏海洋大学	一种含吡啶盐的喹唑啉酮衍生物及其制备方法与应用
CN117088764A (zh) *	2023-08-24	2023-11-21	济南大学	一种头孢地尔关键中间体的合成和后处理方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3487079A (en) *	1966-01-14	1969-12-30	Bristol Myers Co	Certain alpha-amino bicyclic beta-lactam carboxylic acids
US3926983A (en) *	1974-08-30	1975-12-16	Squibb & Sons Inc	3-Heterothio{8 (alkoxycarbonyl)thioacetyl{9 cephalosporanic derivatives
US4268509A (en)	1978-07-10	1981-05-19	Fujisawa Pharmaceutical Co., Ltd.	New cephem compounds and processes for preparation thereof
JPS5511600A (en) *	1978-07-10	1980-01-26	Fujisawa Pharmaceut Co Ltd	Cephem compound, its salt, their preparation and remedy and prophylactic for microbism containing mainly the same
JPS56118085A (en) *	1980-02-25	1981-09-16	Takeda Chem Ind Ltd	2-methylcephalosporin derivative and its preparation
GB8816519D0 (en)	1987-07-23	1988-08-17	Ici Plc	Antibiotic compounds
JPH0228185A (ja)	1988-04-14	1990-01-30	Tanabe Seiyaku Co Ltd	セファロスポリン化合物及びその合成中間体
PH25965A (en)	1988-06-06	1992-01-13	Fujisawa Pharmaceutical Co	New cephem compounds which have antimicrobial activities
GB8813945D0 (en)	1988-06-13	1988-07-20	Fujisawa Pharmaceutical Co	New cephem compounds & process for preparation thereof
GB8817653D0 (en)	1988-07-25	1988-09-01	Fujisawa Pharmaceutical Co	New cephem compounds & processes for preparation thereof
US5143910A (en)	1989-09-07	1992-09-01	Shionogi & Co., Ltd.	Piperaziniocephalosporins
GB9005246D0 (en)	1990-03-08	1990-05-02	Fujisawa Pharmaceutical Co	New cephem compounds and processes for preparation thereof
US5095012A (en) *	1990-08-23	1992-03-10	Bristol-Myers Squibb Company	Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
GB9111406D0 (en)	1991-05-28	1991-07-17	Fujisawa Pharmaceutical Co	New cephem compounds and processes for preparation thereof
GB9118672D0 (en)	1991-08-30	1991-10-16	Fujisawa Pharmaceutical Co	New cephem compounds and processes for preparation thereof
DK0620225T3 (da)	1993-04-16	2003-03-17	Basilea Pharmaceutica Ag	Cephalosporinderivater
EP0838465A1 (en)	1996-10-22	1998-04-29	F. Hoffmann-La Roche Ag	Pyridinium-substituted (lactamylvinyl)cephalosporin derivatives, their preparation and their use as antibiotics
DK0841339T3 (da)	1996-11-06	2007-07-02	Basilea Pharmaceutica Ag	Vinylpyrrolidinon-cephalosporinderivater
JP2003078440A (ja)	2001-08-30	2003-03-14	Kyocera Corp	高周波スイッチ回路
TW200305422A (en) *	2002-03-18	2003-11-01	Shionogi & Co	Broad spectrum cefem compounds
JP4557859B2 (ja)	2005-09-29	2010-10-06	富士通株式会社	周波数分割多重送受信装置及び送受信方法
EP1994035A1 (en)	2006-03-16	2008-11-26	Astellas Pharma Inc.	Cephem compounds and use as antimicrobial agents
KR101655961B1 (ko) *	2008-10-31	2016-09-08	시오노기세야쿠 가부시키가이샤	카테콜기를 갖는 세팔로스포린류
IN2012CN09242A (me) *	2010-04-05	2015-08-21	Shionogi & Co
US8883773B2 (en) *	2010-04-05	2014-11-11	Shionogi & Co., Ltd.	Cephem compound having pseudo-catechol group
US9085589B2 (en) *	2010-04-28	2015-07-21	Shionogi & Co., Ltd.	Cephem derivative
EP2621276B1 (en) *	2010-09-30	2017-12-27	Merck Sharp & Dohme Corp.	2-alkoxy pyrimidine pde10 inhibitors
KR20140039202A (ko) *	2011-04-28	2014-04-01	시오노기세야쿠 가부시키가이샤	카테콜 또는 의사 카테콜 구조를 갖는 신규 세펨 화합물
CN103619853A (zh) *	2011-06-27	2014-03-05	盐野义制药株式会社	具有吡啶鎓基的头孢烯化合物
TWI547496B (zh) *	2011-10-04	2016-09-01	葛蘭素集團公司	抗菌化合物
CN103958527A (zh) *	2011-10-04	2014-07-30	盐野义制药株式会社	具有儿茶酚基团的头孢烯衍生物
BR112015008905A2 (pt)	2012-10-29	2017-07-04	Shionogi & Co	processos para a produção de intermediários de compostos de 2-alquil cefem

2013
- 2013-10-25 UY UY0001035103A patent/UY35103A/es unknown
- 2013-10-29 CN CN201710928528.9A patent/CN107652310A/zh active Pending
- 2013-10-29 CN CN201380068743.6A patent/CN104884460B/zh not_active Expired - Fee Related
- 2013-10-29 EP EP13820853.3A patent/EP2917223B1/en active Active
- 2013-10-29 CA CA2889746A patent/CA2889746A1/en not_active Abandoned
- 2013-10-29 PL PL13820853T patent/PL2917223T3/pl unknown
- 2013-10-29 MY MYPI2015701345A patent/MY176987A/en unknown
- 2013-10-29 EA EA201590844A patent/EA031881B1/ru not_active IP Right Cessation
- 2013-10-29 UA UAA201505213A patent/UA117666C2/uk unknown
- 2013-10-29 TR TR2019/04001T patent/TR201904001T4/tr unknown
- 2013-10-29 BR BR122016025225-6A patent/BR122016025225A2/pt not_active Application Discontinuation
- 2013-10-29 NZ NZ628527A patent/NZ628527A/en not_active IP Right Cessation
- 2013-10-29 DK DK13820853.3T patent/DK2917223T3/en active
- 2013-10-29 HR HRP20190603TT patent/HRP20190603T1/hr unknown
- 2013-10-29 RS RS20190449A patent/RS58611B1/sr unknown
- 2013-10-29 MX MX2015005429A patent/MX365534B/es active IP Right Grant
- 2013-10-29 AU AU2013340469A patent/AU2013340469B2/en not_active Ceased
- 2013-10-29 MA MA38039A patent/MA38039A1/fr unknown
- 2013-10-29 PT PT13820853T patent/PT2917223T/pt unknown
- 2013-10-29 US US14/439,219 patent/US20150299223A1/en not_active Abandoned
- 2013-10-29 PE PE2015000527A patent/PE20151204A1/es unknown
- 2013-10-29 JP JP2015538583A patent/JP6316830B2/ja active Active
- 2013-10-29 LT LTEP13820853.3T patent/LT2917223T/lt unknown
- 2013-10-29 ES ES13820853T patent/ES2717923T3/es active Active
- 2013-10-29 SI SI201331401T patent/SI2917223T1/sl unknown
- 2013-10-29 AR ARP130103941A patent/AR093261A1/es unknown
- 2013-10-29 ME MEP-2019-61A patent/ME03359B/me unknown
- 2013-10-29 HU HUE13820853A patent/HUE042664T2/hu unknown
- 2013-10-29 BR BR112015009460A patent/BR112015009460A2/pt not_active IP Right Cessation
- 2013-10-29 SM SM20190209T patent/SMT201900209T1/it unknown
- 2013-10-29 SG SG10201703589TA patent/SG10201703589TA/en unknown
- 2013-10-29 SG SG11201502540RA patent/SG11201502540RA/en unknown
- 2013-10-29 WO PCT/IB2013/002423 patent/WO2014068388A1/en not_active Ceased
- 2013-10-29 TW TW102139095A patent/TWI625333B/zh not_active IP Right Cessation
- 2013-10-30 KR KR1020157010699A patent/KR20150081428A/ko not_active Ceased
2015
- 2015-03-30 ZA ZA2015/02174A patent/ZA201502174B/en unknown
- 2015-04-02 IL IL238149A patent/IL238149A/en active IP Right Grant
- 2015-04-23 PH PH12015500914A patent/PH12015500914A1/en unknown
- 2015-04-24 CL CL2015001084A patent/CL2015001084A1/es unknown
- 2015-04-29 CR CR20150224A patent/CR20150224A/es unknown
2017
- 2017-02-02 AU AU2017200717A patent/AU2017200717A1/en not_active Abandoned
- 2017-04-18 US US15/490,220 patent/US10174053B2/en not_active Expired - Fee Related
- 2017-04-24 PH PH12017500755A patent/PH12017500755A1/en unknown
2019
- 2019-04-08 CY CY20191100387T patent/CY1121721T1/el unknown

Also Published As

Publication number	Publication date
NZ628527A (en)	2017-03-31
JP2015534995A (ja)	2015-12-07
US10174053B2 (en)	2019-01-08
ES2717923T3 (es)	2019-06-26
MA38039A1 (fr)	2016-05-31
HRP20190603T1 (hr)	2019-05-31
CL2015001084A1 (es)	2015-08-28
PL2917223T3 (pl)	2019-06-28
PH12015500914B1 (en)	2015-06-29
CY1121721T1 (el)	2020-07-31
SG10201703589TA (en)	2017-06-29
MX2015005429A (es)	2015-07-21
CA2889746A1 (en)	2014-05-08
EP2917223B1 (en)	2019-01-16
CN104884460A (zh)	2015-09-02
HK1214826A1 (en)	2016-08-05
EP2917223A1 (en)	2015-09-16
BR112015009460A2 (pt)	2017-07-04
HUE042664T2 (hu)	2019-07-29
PH12015500914A1 (en)	2015-06-29
DK2917223T3 (en)	2019-04-15
SMT201900209T1 (it)	2019-07-11
MY176987A (en)	2020-08-31
EA201590844A1 (ru)	2015-09-30
ZA201502174B (en)	2016-01-27
CR20150224A (es)	2015-10-19
WO2014068388A1 (en)	2014-05-08
SG11201502540RA (en)	2015-05-28
CN107652310A (zh)	2018-02-02
BR122016025225A2 (pt)	2019-07-30
CN104884460B (zh)	2017-11-03
UY35103A (es)	2014-05-30
UA117666C2 (uk)	2018-09-10
AU2013340469B2 (en)	2016-11-03
TW201431863A (zh)	2014-08-16
US20170281532A1 (en)	2017-10-05
AU2013340469A1 (en)	2015-04-16
KR20150081428A (ko)	2015-07-14
US20150299223A1 (en)	2015-10-22
TWI625333B (zh)	2018-06-01
AU2017200717A1 (en)	2017-02-23
IL238149A (en)	2017-09-28
EA031881B1 (ru)	2019-03-29
RS58611B1 (sr)	2019-05-31
JP6316830B2 (ja)	2018-04-25
PH12017500755A1 (en)	2018-01-29
TR201904001T4 (tr)	2019-04-22
MX365534B (es)	2019-06-06
PT2917223T (pt)	2019-05-17
SI2917223T1 (sl)	2019-05-31
PE20151204A1 (es)	2015-09-03
AR093261A1 (es)	2015-05-27
LT2917223T (lt)	2019-04-10

Publication	Publication Date	Title
ME03359B (me)	2019-10-20	2 suptiтuisana cefemska jedinjenja
HRP20171005T1 (hr)	2017-09-22	Spojevi imidazopirolidinona
HRP20170226T1 (hr)	2017-04-07	Spoj pirazinkarboksamida
EP2763896A4 (en)	2015-03-11	UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da)	2021-02-22	Polymercoatings
DK2825087T3 (da)	2019-05-13	Otoscanner
EP2809145A4 (en)	2015-09-16	CHLOROPLAST TRANSIT PEPTIDES
DK2839013T3 (da)	2020-09-14	Ikke-disruptiv-gen-targetering
EP2814472A4 (en)	2015-11-04	DITHIOAMINE REDUCING AGENTS
EP2824794A4 (en)	2016-02-24	Charging cable
EP2847405A4 (en)	2016-03-02	DOOR CLOSURE SYSTEM
EP2805877A4 (en)	2015-09-09	UNDER HOOD
PT3068786T (pt)	2018-07-26	Compostos de pirazolopirimidina
DK2873977T3 (da)	2020-06-08	Dobbeltdækker-rørdispenser
CO6990736A2 (es)	2014-07-10	Pirrolidina-2-carboxamidas sustituídas
DK2854722T3 (da)	2020-08-24	Stomipose
EP2831482A4 (en)	2015-12-16	Flange gasket
DK2825157T3 (da)	2019-01-02	Aminosyrelipider
DK2804611T3 (da)	2020-11-09	Chitosanafledte forbindelser
EP2862179A4 (en)	2016-06-01	FUEL CURRENT INSPECTION PROBE
EP2869113A4 (en)	2015-12-02	DISPLAY DEVICE FOR VEHICLE
EP2801315A4 (en)	2015-09-09	SCANNING ENDOSCOPE DEVICE
EP2920370A4 (en)	2016-08-03	POST
DK2831122T3 (da)	2016-05-17	Anthocyanidin-kompleks
DK2885638T3 (da)	2020-07-20	Molekylenet